BOB International: Maintaining Deqi Pharmaceuticals (06996)'s “Buy” Rating, Raising the Target Price to HK$4.6
Deqi Pharmaceuticals (6996.HK): Reached a commercial cooperation with Hanson Pharmaceuticals to increase product volume visibility; increase target prices
Deqi Pharmaceutical (6996.HK): Core products have long-term space, huge self-research capabilities have entered a critical verification period
Deqi Pharmaceutical-B (6996.HK): The R&D pipeline is rich and the indications for celinisol are increasing
Deqi Pharmaceutical (6996.HK): The early cancer pipeline from introduction to self-development is highly differentiated and has great potential
Deqi Pharmaceutical-B (06996.HK): Commercialization process begins, focusing on global R&D progress
Deqi Pharmaceutical-B (06996.HK): Sivio's commercialization exceeds expectations, and the global equity pipeline is worth looking forward to
Deqi Pharmaceutical (6996.HK): Celinisol has been approved for marketing in many countries and various clinical pipelines are progressing smoothly
Deqi Pharmaceutical-B (06996.HK): SELINEXOR is about to be marketed in China, ATG017 teams up with O drugs to attack solid tumors
Deqi Pharmaceutical-B (06996.HK): Celinisol starts commercialization in Asia Pacific and the R&D pipeline is progressing positively
Deqi Pharmaceutical-B (6996.HK): Commercialization of SELINEXOR is imminent and has abundant independent research and development pipelines
Deqi Pharmaceutical-B (06996.HK): Differentiated pipeline layout; commercialization of Selinisol is imminent
Deqi Pharmaceutical-B (06996.HK): SELINEXOR progressed successfully to deploy CD73 small molecule inhibitors
Deqi Pharmaceutical-B (06996.HK): A biotech company with competitive and unique treatment solutions
Deqi Pharmaceutical-B (06996.HK): Focus on being globally competitive differentiated targets
Deqi Pharmaceutical (06996.HK): Deqi Pharmaceutical and CALITHERA have reached a cooperation ATG-037 is expected to start clinical research within the year
Deqi Pharmaceutical (06996.HK): XOP1 inhibitors enter new recommendations for hematoma treatment
Deqi Pharmaceutical (6996.HK): IPO Review
IPO News: Deqi Pharmaceutical Co., Ltd. (6996.HK)
IPO Report: Deqi Pharmaceutical Co., Ltd. (6996.HK)
No Data